DongBJHauckWWGambertoglioJGGeeLWhiteJRBubpJLBioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA1997;277:1205–13.
3.
DongBJYoungVRRapoportB. The nonequivalence of thyroid products (letter). Drug Intell Clin Pharm1986;20:77–8.
4.
WadmanM. Drug company suppressed publication of research. Nature1996;381:4.
5.
MayorGHOrlandoTKurtzNM. Limitations of levothyroxine bioequivalence evaluation: Analysis of an attempted study. Am J Ther1995;2:417–32.
6.
ZinbergDS. A cautionary tale (editorial). Science1996;273:411.
7.
CohenWFloridaRGoeWR. University—industry research centers in the United States. Pittsburgh: Center for Economic Development, Heinz School of Public Policy and Management, Carnegie Mellon University, 1994:1–38.
8.
RennieDYankVEmanuelL. When authorship fails: A proposal to make contributors accountable. JAMA1997;278:579–84.
9.
MathesonCColletteDRCramerRLOrrJHopeflAPaloucekFP. Reactions to fosphenytoin editorial and review article. Am J Health-Syst Pharm1997;54:441–9.
10.
DavidoffF. Where's the bias? Ann Intern Med1997;126:986–8.
11.
HortonR. The signature of responsibility. Lancet1997;350:5–6.
12.
EnglerRLCovellJWFriedmanPKitcherPSPetersRM. Misrepresentation and responsibilities in medical research. N Engl J Med1987;319:1383–9.
13.
GoodmanB. Cancer center misconduct case raises thorny issues. Scientist1997;11(16):1,6–7.
